FiercePharma

Ariosa's Harmony™ Prenatal Test shown to be superior to conventional pregnancy screening for Down syndrome (Trisomy 21) in largest clinical trial

New England Journal of Medicine publishes findings of largest non-invasive prenatal testing (NIPT) study involving more than 18,500 expectant mothers "This landmark study supports the use of NIPT as a ...
FiercePharma

Ariosa grants licenses to laboratories to perform non-invasive prenatal testing (NIPT) based on Harmony™ Prenatal Test technology

SAN JOSE, Calif., June 11, 2015 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX:RHHBY). Ariosa Diagnostics, Inc., a global leader in non-invasive prenatal testing (NIPT) technology and maker of the Harmony ...
The Trentonian

BioReference Laboratories Acquires U.S. Ariosa Centralized Laboratory Prenatal Testing Business

BioReference announced the acquisition of the U.S. Ariosa centralized laboratory prenatal testing business from Roche. Ariosa’s non invasive prenatal screening (NIPS) test, the Harmony Prenatal Test, ...
TASS

Microarray technology proves superior to sequencing for non-invasive prenatal testing

Ariosa Diagnostics announced that its scientists have successfully tested and implemented a microarray DNA quantification method for Ariosa's Harmony Non-Invasive Prenatal Test SAN JOSE, California, ...
TASS

Harmony Prenatal Test to be superior to conventional pregnancy screening for Down syndrome

New England Journal of Medicine publishes findings of largest non-invasive prenatal testing study involving more than 18,500 expectant mothers SAN JOSE, California, April 2 /PRNewswire/ -- Roche (SIX: ...
Nasdaq

BioReference Laboratories Acquires U.S. Ariosa Centralized Laboratory Prenatal Testing Business

Ariosa's non invasive prenatal screening (NIPS) test, the Harmony Prenatal Test, is one of the most widely studied tests utilized in prenatal screening. The test has been performed in over 1.5 million ...